Eldrid Borgan1, Beathe Sitter2, Tone Frost Bathen2, Steinar Lundgren2,3, Hilde Johnsen1, Ole Christian Lingjrde4, Therese Srlie1,4, Anne-Lise Brresen-Dale1,5, Ingrid Susann Gribbestad2
1Department of Genetics, Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway; 2Department of Circulation and Imaging, NTNU, Trondheim, Norway; 3Deptartment of Oncology, St. Olavs University Hospital, Trondheim, Norway; 4Department of Informatics, University of Oslo, Oslo, Norway; 5Faculty division, The Norwegian Radium Hospital, Faculty of Medicine, University of Oslo, Oslo, Norway
Joint analysis of gene expression microarrays and HR MAS metabolic profiles reveals differences within the luminal A tumors, a gene expression-based subtype of breast cancer. The luminal A subgroup is the largest and is associated with positive ER status and relatively good prognosis. However, a certain fraction of patients with luminal A breast cancer have a poor outcome. Preliminary results of 29 tumors from breast cancer patients show that differences in biochemistry and gene expression for two subgroups of luminal A tumors, identified by their metabolic MR profiles, are connected to lipid content and apoptosis.